Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
MNTA > SEC Filings for MNTA > Form 8-K on 18-Jul-2014All Recent SEC Filings




Entry into a Material Definitive Agreement, Financial Statements and

Item 1.01. Entry into a Material Definitive Agreement.

On July 15, 2014, Momenta Pharmaceuticals, Inc. (the "Company") and Vertex Pharmaceuticals Incorporated ("Vertex") entered into the fourth amendment to the sublease agreement (the "Amendment") for Momenta's corporate headquarters at 675 West Kendall Street, Cambridge, Massachusetts (the "Premises"). The Amendment provides that the original sublease for the Premises, as previously amended, will be extended for the period commencing on May 1, 2015 and ending on April 30, 2018 and that annual base rent for the Premises payable by the Company during the extension period will be $4,824,921, or $61.50 per square foot. The Amendment will become effective upon the date that Vertex's landlord for the Premises consents to the Amendment.

The Amendment contains a right of first offer ("ROFO") for the Company as to space currently rented by Genzyme Corporation from Vertex on the fifth and sixth floors of the building, provided that the ROFO will be subject to any existing rights of Genzyme to such space.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)                 Exhibits.

No.                                     Description
10.1      Fourth Amendment to Sublease, dated June 14, 2014, by and between Vertex
          Pharmaceuticals Incorporated and Momenta Pharmaceuticals, Inc.

  Add MNTA to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for MNTA - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.